The global animal antibiotics and antimicrobials size was valued US$ XX billion in 2020 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of 6.85 % during the forecast period (2022-2029).
Antibiotic resistance is an important public health issue that all sectors using antibiotics must work together to address. The animal health industry is committed to protecting the health of animals and people by producing safe food and animal products. Antimicrobial stewardship is important to prevent, control and treat bacterial illnesses in animals. In animal health, we are committed to promoting science-based policies that enhance antimicrobial stewardship and to working with veterinarians and food producers to implement good stewardship practices. Thus the popularity of animal antibiotics and antimicrobials among animal husbandry is driving the growth of the market in the forecast period.
The global animal antibiotics and antimicrobials market growth is driven by the increasing presence of bacterial infections, such as pneumonia and skin infections will drive the growth of the market in the forecast period.
Rising awareness among consumers will stoke market growth in the forecast period
Growing urbanization, increasing disposable income and increasing demand for animals as a pet is encouraging growth in the animal antimicrobials and antibiotics market. Increasing animal disease outbreaks are touted to play a key role in aiding the expansion of the global animal antimicrobials and antibiotics market. The growing livestock population is anticipated to further assist the animal antimicrobials and antibiotics market.
Awareness of animal illness and other diseases spread in animals and livestock which makes it difficult to have animal-based products edible for human use is leading towards animal antimicrobials and antibiotics to cure these illnesses in animals.
Investments in biosecurity to curb animal diseases drive the market growth
Animal diseases, for instance, African swine fever or avian influenza are increasing day after day, thereby affecting new areas as well. Therefore, reducing probable risks by means of implementing procedures developed for avoiding the spread and introduction of pathogens in the animal population is expected to create lucrative growth opportunities for animal antibiotics and the antimicrobials market. Heavy efforts have been taken by veterinary services to enter into collaboration with various stakeholders, thereby developing appropriate biosecurity measures, positively impacting the development of animal antibiotics and antimicrobials market. OIE Regional Commission for Europe is planning to implement biosecurity plans for enhancing biosecurity in non-commercial and backyard farms as well, thereby preventing the spread of diseases. Growing measures taken to prevent the spread of animal diseases is further expected to contribute towards the growth of animal antibiotics and antimicrobials market.
Shortage of new antibiotics is likely to hinder the market growth
On the contrary, the shortage of new antibiotics coupled with increasing resistance to antibiotics and antimicrobials is expected to hinder the growth of the market in the forecast period.
COVID-19 Impact Analysis
The growth of the global animal antimicrobials and antibiotics market is likely to be influenced by the rising cases of zoonotic diseases, such as SARS-CoV-2 induced Covid-19, worldwide. In addition, rising demand for animal-derived food items, pet insurance, and implementation of rules pertaining to the prevention of animal disease spread is expected to augur well for the market. There has been increased spending on animal health in recent years, which is expected to drive demand for animal antimicrobials and antibiotics shortly. Thus the pandemic does not affect the market in the forecast period.
The tetracycline segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)
Tetracycline is a broad-spectrum antibiotic from the same family as oxytetracycline, doxycycline, minocycline, and others. The tetracycline antibiotics are bacteriostatic. Their mechanism of action is through the reversible binding of bacterial 30S ribosomes and the alteration of the bacterial cytoplasmic membrane. Tetracycline antibiotics are used to treat bacterial infections due to aerobic, gram-positive and gram-negative bacteria, mycoplasma, rickettsiae, chlamydia, and some protozoa. Doxycycline and minocycline have greater lipid solubility than tetracycline and may be more effective against some Staphylococcal infections. Certain gram-negative bacteria, particularly Pseudomonas and some enteric bacteria, are resistant to tetracycline.
Oral tetracycline is used in dogs and cats to treat susceptible bacterial infections and infections due to other susceptible organisms. Tetracycline has some immunomodulatory properties and may be used with steroids and niacinamide to treat cutaneous discoid lupus erythematosus of dogs. When used to treat autoimmune disease, there may be a considerable lag (one to two months) before appreciable improvement is seen.
Ophthalmic tetracycline is used to treat Chlamydial, Mycoplasma, and non-specific conjunctivitis in the cat. Although topical ophthalmic tetracycline is useful for improving the clinical signs associated with Chlamydia, systemic treatment with doxycycline may be necessary to eliminate the organism.
Penicillin has positive market growth in the forecast period. Penicillin for dogs is most often prescribed as part of treatment for a bacterial infection. It is commonly prescribed for infections of the urinary tract, lungs, and kidneys. A topical penicillin lotion or ointment may be used to treat various skin infections, and penicillin is also sometimes used in treating leptospirosis, wounds, and dental infections.
Owing to several possible serious side effects, veterinarians are prescribing penicillin for dogs with less frequency than they once did. They are more likely to prescribe a different antibiotic if another treatment is available. Possible side effects of penicillin include yeast infections, vomiting, and diarrhoea. Dogs are also prone to allergic reactions that can include eczema, swelling, and itching. Even more serious, this antibiotic can sometimes cause kidney damage, liver damage, and a weakened immune system.
Macrolides and lincosamides are used for the treatment of diseases that are common in food-producing animals including medication of large groups of animals. They are critically important for animal health and therefore they must be used prudently to contain resistance against major animal pathogens. In addition, these are listed by WHO (AGISAR, 2009) as critically important for the treatment of certain zoonotic infections in humans and risk mitigation measures are needed to reduce the risk for the spread of resistance between animals and humans.
North America region holds the largest market share global animal antibiotics and antimicrobials market
North America region is dominating the global animal antibiotics and antimicrobials market accounted for the largest market share in 2020, owing to the factors such as high ownership cases of companion animals and excessive livestock products consumption is contributing towards the notable growth of North American animal antibiotics and antimicrobials market. In addition, key players in the region are taking immense efforts in making huge investments for introducing drugs that would cater to the treatment of animal diseases. On the other hand, the Asia-Pacific region is expected to witness the highest growth rate during the forecast period. This can be mainly attributed to the growing livestock population, increasing pet adoption, rising awareness about animal health, progressive urbanization, changing dietary habits, and growing per capita animal health expenditure in this region.
The Animal Antibiotics and Antimicrobials market is moderately competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Zoetis, Endovac Animal Health, Merck & Co., Inc., Ceva, Eli Lilly and Company, Bayer AG, Dechra Pharmaceuticals PLC, Virbac, Vetoquinol S.A, Boehringer Ingelheim GmbH, Sanofi, Bioniche Animal Health, Elanco, Fort Dodge Animal Health and among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the animal antibiotics and antimicrobials market globally.
Overview: Zoetis Inc., incorporated on July 25, 2012, is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories. As of December 31, 2016, the Company had approximately 300 product lines, including products for both livestock and companion animals across each of its product categories. As of December 31, 2016, the Company marketed its products to veterinarians and livestock producers located in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America.
Product Portfolio: The Company’s portfolio is comprised of anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Key Development: In June 2018, Zoetis caring for animals in the age of antibiotic resistance, to overcome various challenges company initiates at the R&D, regulatory, manufacturing and commercial fronts to tackle the challenges of antibiotic resistance and still ensure the care and welfare of sick animals. Due to its large product portfolio including medicines, vaccines, diagnostics and genetic solutions, Zoetis is well-positioned to support animals from disease detection to prevention and treatment.
Get your free sample proposal with a single click!